Topical 5% imiquimod for the therapy of actinic cheilitis.
作者： Kathleen J. Smith , Margeruite Germain , Josef Yeager , Henry Skelton
关键词:
摘要: Abstract Background: Tissue-destructive and more selective cytotoxic therapies are the main methods used to treat actinic cheilitis. A topical immune stimulant, 5% imiquimod cream, has recently been for treatment of cutaneous epithelial malignancies including squamous cell carcinoma in situ basal carcinoma. Objective: Our aim was review results patients who had treated cheilitis with cream. Methods: identified 15 biopsy-proven 3 times weekly 4 6 weeks. All histories consistent facial herpes simplex or documented prior eruptions were oral valcyclovir, 1 g/d, during therapy. Results: showed clinical clearing their at weeks after discontinuation imiquimod. Sixty percent experienced a moderate marked increased local reaction consisting erythema, induration, erosions ulcerations, which some cases continued through period Conclusion: Imiquimod appears have role However, dose duration therapy, as well long-term efficacy, need be established; reactions expected may not improve (J Am Acad Dermatol 2002;47:497-501.)
jaad.org
elsevier.com
sci-hub.se 参考文章(19)
A. NEDER, O. NAHLIELI, I. KAPLAN, CO2 laser used in surgical treatment of actinic cheilitis Journal of Clinical Laser Medicine & Surgery. ,vol. 10, pp. 373- 375 ,(1992) , 10.1089/CLM.1992.10.373
RICHARD E. FITZPATRICK, MITCHEL P. GOLDMAN, JAVIER RUIZ-ESPARZA, Clinical advantage of the CO2 laser superpulsed mode. Treatment of verruca vulgaris, seborrheic keratoses, lentigines, and actinic cheilitis. The Journal of Dermatologic Surgery and Oncology. ,vol. 20, pp. 449- 456 ,(1992) , 10.1111/J.1524-4725.1994.TB03215.X
RAYMOND G. DUFRESNE, MONIKA U. CURLIN, Actinic Cheilitis Dermatologic Surgery. ,vol. 23, pp. 15- 21 ,(1997) , 10.1111/J.1524-4725.1997.TB00002.X
Karl R. Beutner, John K. Geisse, Donita Helman, Terry L. Fox, Angela Ginkeld, Mary L. Owens, Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream Journal of The American Academy of Dermatology. ,vol. 41, pp. 1002- 1007 ,(1999) , 10.1016/S0190-9622(99)70261-6
G. Trinchieri, P. Scott, Interleukin-12: a proinflammatory cytokine with immunoregulatory functions. Research in Immunology. ,vol. 146, pp. 423- 431 ,(1995) , 10.1016/0923-2494(96)83011-2
Tamara L. Wagner, Cory L. Ahonen, Aimee M. Couture, Sheila J. Gibson, Richard L. Miller, Rose M. Smith, Michael J. Reiter, John P. Vasilakos, Mark A. Tomai, Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cellular Immunology. ,vol. 191, pp. 10- 19 ,(1999) , 10.1006/CIMM.1998.1406
James Pehoushek, Kathleen J. Smith, Imiquimod and 5% Fluorouracil Therapy for Anal and Perianal SquamousCell Carcinoma In Situ in an HIV-1–Positive Man Archives of Dermatology. ,vol. 137, pp. 14- 16 ,(2001) , 10.1001/ARCHDERM.137.1.14
Robert P. Burns, Barbara Ferbel, Mark Tomai, Richard Miller, Anthony A. Gaspari, The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clinical Immunology. ,vol. 94, pp. 13- 23 ,(2000) , 10.1006/CLIM.1999.4804
Linda M. Imbertson, Aimee M. Couture, Sheila J. Gibson, Rose M.A. Smith, Richard L. Miller, Michael J. Reiter, Tamara L. Wagner, Mark A. Tomai, Joseph M. Beaurline, Cytokine Induction in Hairless Mouse and Rat Skin After Topical Application of the Immune Response Modifiers Imiquimod and S-28463 Journal of Investigative Dermatology. ,vol. 110, pp. 734- 739 ,(1998) , 10.1046/J.1523-1747.1998.00174.X
IRVING S. COOPER, ARNOLD St. J. LEE, Cryostatic congelation: a system for producing a limited, controlled region of cooling or freezing of biologic tissues. Journal of Nervous and Mental Disease. ,vol. 133, pp. 259- 263 ,(1961) , 10.1097/00005053-196109000-00013